Elevated preoperative CA125 levels predicts poor prognosis of hilar cholangiocarcinoma receiving radical surgery - 11/11/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Hilar cholangiocarcinoma is a challenging disease for hepatobiliary surgeons. |
• | There is still no good tumor marker to predict the prognosis of HCCA. |
• | CA125 can be used for predicting long-term prognosis after radical surgery for HCCA. |
• | CA125 is shown in this article to have the potential to guide HCCA surgical resection. |
Abstract |
Background |
Preoperative serum carbohydrate antigen 125 (CA125) is used to judge the diagnosis and prognosis of various tumors. However, the relationship between preoperative serum CA125 and prognosis of hilar cholangiocarcinoma (HCCA) has not been proven. This study aims to evaluate preoperative serum CA125 in predicting the prognosis of HCCA after resection.
Methods |
A total of 233 patients after radical resection of HCCA were included. The associations between the levels of preoperative serum CA125 and the clinicopathological characteristics of patients were analyzed. Survival curves were calculated using the Kaplan–Meier method. Univariate and multivariate Cox regression models were used to identify independent risk factors associated with recurrence-free survival (RFS) and overall survival (OS).
Results |
Among 233 patients, 198 (84.97%) with normal CA125 levels (≤35 U/mL) had better OS and RFS than 35 (15.02%) patients with higher CA125 levels (>35 U/mL). Preoperative serum CA125 was significantly correlated with tumor size, Bismuth–Corlette classification, microvascular invasion and carcinoembryonic antigen (CEA) (p < 0.001, p = 0.040, p = 0.019 and p = 0.042, respectively). The results of multivariable Cox regression showed that preoperative serum CA125 >35 U/mL (p = 0.002, HR = 1.910 for OS; p = 0.006, HR = 1.755 for RFS), tumor classification (p < 0.001, HR = 2.110 for OS; p = 0.006, HR = 1.730 for RFS), lymph node metastasis (p < 0.001, HR = 1.795 for OS; p < 0.001, HR = 1.842 for RFS) and major vascular invasion (p = 0.002, HR = 1.639 for OS; p = 0.005, HR = 1.547 for RFS) were independent risk factors for both OS and RFS.
Conclusions |
Preoperative serum CA125 is a good tumor marker for predicting prognosis after radical surgery for HCCA.
Le texte complet de cet article est disponible en PDF.Keywords : Hilar cholangiocarcinoma, CA125, Prognosis
Plan
Vol 45 - N° 6
Article 101695- novembre 2021 Retour au numéro
Article précédent
- Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion
- Lorraine Blaise, Helena Pereira, Valérie Vilgrain, Olivier Sutter, Elia Gigante, Aurélie Walter, Nathalie Ganne-Carrié, Pierre Nahon, Mohamed Bouattour, Marco Dioguardi Burgio, Véronique Grando, Gisèle Nkontchou, Olivier Seror, Jean-Charles Nault
- Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis
- Xiaofei Li, Yuexiao Yu, Liwen Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?